Eli Lilly and (LLY)
Eli Lilly and Statistics
Share Statistics
Eli Lilly and has 947.99M shares outstanding. The number of shares has increased by -0.15% in one year.
Shares Outstanding | 947.99M |
Shares Change (YoY) | -0.15% |
Shares Change (QoQ) | -0.12% |
Owned by Institutions (%) | 86.11% |
Shares Floating | 849.99M |
Failed to Deliver (FTD) Shares | 147 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 7.22M, so 0.76% of the outstanding shares have been sold short.
Short Interest | 7.22M |
Short % of Shares Out | 0.76% |
Short % of Float | 0.85% |
Short Ratio (days to cover) | 1.91 |
Valuation Ratios
The PE ratio is 65.43 and the forward PE ratio is 35.77. Eli Lilly and's PEG ratio is 0.64.
PE Ratio | 65.43 |
Forward PE | 35.77 |
PS Ratio | 15.38 |
Forward PS | 7.7 |
PB Ratio | 48.38 |
P/FCF Ratio | 1672.46 |
PEG Ratio | 0.64 |
Enterprise Valuation
Eli Lilly and has an Enterprise Value (EV) of 547.14B.
EV / Earnings | 51.67 |
EV / Sales | 12.15 |
EV / EBITDA | 35.93 |
EV / EBIT | 42.42 |
EV / FCF | 1320.64 |
Financial Position
The company has a current ratio of 0.12, with a Debt / Equity ratio of 2.35.
Current Ratio | 0.12 |
Quick Ratio | 0.12 |
Debt / Equity | 2.35 |
Total Debt / Capitalization | 70.14 |
Cash Flow / Debt | 0.26 |
Interest Coverage | 21.31 |
Financial Efficiency
Return on equity (ROE) is 0.74% and return on capital (ROIC) is 22.46%.
Return on Equity (ROE) | 0.74% |
Return on Assets (ROA) | 0.13% |
Return on Capital (ROIC) | 22.46% |
Revenue Per Employee | $958,355.32 |
Profits Per Employee | $225,319.15 |
Employee Count | 47,000 |
Asset Turnover | 0.57 |
Inventory Turnover | n/a |
Taxes
Income Tax | 2.09B |
Effective Tax Rate | 0.16 |
Stock Price Statistics
The stock price has increased by 5.41% in the last 52 weeks. The beta is 0.34, so Eli Lilly and's price volatility has been higher than the market average.
Beta | 0.34 |
52-Week Price Change | 5.41% |
50-Day Moving Average | 842.5 |
200-Day Moving Average | 855.91 |
Relative Strength Index (RSI) | 43.39 |
Average Volume (20 Days) | 3.63M |
Income Statement
In the last 12 months, Eli Lilly and had revenue of 45.04B and earned 10.59B in profits. Earnings per share was 11.8.
Revenue | 45.04B |
Gross Profit | 36.62B |
Operating Income | 12.9B |
Net Income | 10.59B |
EBITDA | 15.23B |
EBIT | 12.9B |
Earnings Per Share (EPS) | 11.8 |
Balance Sheet
The company has 3.27B in cash and 33.64B in debt, giving a net cash position of -30.38B.
Cash & Cash Equivalents | 3.27B |
Total Debt | 33.64B |
Net Cash | -30.38B |
Retained Earnings | 0 |
Total Assets | 78.71B |
Working Capital | -24.86B |
Cash Flow
In the last 12 months, operating cash flow was 8.82B and capital expenditures -8.4B, giving a free cash flow of 414.3M.
Operating Cash Flow | 8.82B |
Capital Expenditures | -8.4B |
Free Cash Flow | 414.3M |
FCF Per Share | 0.46 |
Margins
Gross margin is 81.31%, with operating and profit margins of 28.64% and 23.51%.
Gross Margin | 81.31% |
Operating Margin | 28.64% |
Pretax Margin | 28.15% |
Profit Margin | 23.51% |
EBITDA Margin | 33.81% |
EBIT Margin | 28.64% |
FCF Margin | 0.92% |
Dividends & Yields
LLY pays an annual dividend of $6.7, which amounts to a dividend yield of 0.64%.
Dividend Per Share | $6.70 |
Dividend Yield | 0.64% |
Dividend Growth (YoY) | 15.38% |
Payout Ratio | 57.07% |
Earnings Yield | 1.44% |
FCF Yield | 0.05% |
Analyst Forecast
The average price target for LLY is $1001, which is 22.1% higher than the current price. The consensus rating is "Buy".
Price Target | $1001 |
Price Target Difference | 22.1% |
Analyst Consensus | Buy |
Analyst Count | 26 |
Stock Splits
The last stock split was on Oct 16, 1997. It was a forward split with a ratio of 2:1.
Last Split Date | Oct 16, 1997 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 8.04 |
Piotroski F-Score | 5 |